AIM ImmunoTech Stock Price

0.03 (1.46%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 1.46% 2.09 19:48:37
Close Price Low Price High Price Open Price Previous Close
2.09 1.98 2.09 1.98 2.06
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,464 1,159,963 $ 2.06 $ 2,391,417 3,190,974 0.381 - 8.75
Last Trade Time Type Quantity Stock Price Currency
19:50:04 75 $ 2.09 USD

AIM ImmunoTech Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 82.95M 39.69M 2.30M $ 140.00k $ - -9.56 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
2.73M $ - 0.00% 24.00 37.40%

more financials information »

AIM ImmunoTech News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AIM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.812.191.761.961,743,3710.2815.47%
1 Month2.392.621.602.142,728,483-0.30-12.55%
3 Months2.704.301.602.845,329,716-0.61-22.59%
6 Months2.354.301.602.684,708,054-0.26-11.06%
1 Year1.778.750.3812.814,396,0990.3218.08%
3 Years1.968.750.3812.814,234,6590.136.63%
5 Years1.968.750.3812.814,234,6590.136.63%

AIM ImmunoTech Description

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Your Recent History
AIM Immuno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.